Cellular therapy in combination with cytokines improves survival in a xenograft @entity19 model of XXXX .

@entity43 @entity1 @entity353 @entity2047 @entity19 @entity5
UNASSIGNED: Studies have shown enhanced survival of @entity43 @entity1 in which the @entity5 are infiltrated with @entity5 infiltrating lymphocytes and natural killer cells showing the importance of immune surveillance and recognition in @entity43 . Therefore, in this study, we tested cellular immunotherapy and varying combinations of cytokines ( @entity2047 and/or pegylated-IFNa-2b) in a xenograft @entity19 model of @entity43 . SKOV3-AF2 @entity43 cells were injected intra-peritoneally (IP) into athymic @entity19 . On day 7 post- @entity5 cell injection, @entity19 were injected IP with peripheral blood mononuclear cells (PBMC; 5  *  10(6) PBMC) and cytokine combinations [ @entity2047      pegylated-IFNa-2b (IFN)]. Cytokine injections were continued weekly for IFN (12,000 U/injection) and thrice weekly for @entity2047 (4000 U/injection). @entity19 were euthanized when they became moribund due to @entity5 burden at which time @entity5 and ascitic fluid were measured and collected. Treatment efficacy was measured by improved survival at 8 weeks and overall survival by Kaplan-Meier analysis. We observed that the @entity19 tolerated all treatment combinations without significant @entity353 or other apparent illness. @entity19 receiving PBMC plus @entity2047 showed improved median survival (7.3  weeks) compared to @entity19 with no treatment (4.2  weeks), @entity2047 (3.5  weeks), PBMC (4.0  weeks), or PBMC plus @entity2047 (4.3  weeks), although PBMC plus @entity2047 was not statistically different than PBMC plus IFN (5.5  weeks, p  >  0.05). We demonstrate that cytokine-stimulated cellular immune therapy with PBMC and @entity2047 was well tolerated and resulted in survival advantage compared to untreated controls and other cytokine combinations in the nude- @entity19 model.
